Apr 17 |
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
|
Mar 7 |
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
|
Mar 5 |
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
|
Feb 20 |
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
|
Nov 10 |
Lipella's oral GvHD drug candidate gets orphan designation
|
Nov 10 |
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease
|
Oct 25 |
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
|
Oct 24 |
Lipella Pharmaceuticals stock plummets on $2M private placement priced ATM
|
Oct 24 |
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
|
Oct 23 |
Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference
|